Cargando…
Prevention of oxaliplatin-related neurotoxicity by ω-3 PUFAs: A double-blind randomized study of patients receiving oxaliplatin combined with capecitabine for colon cancer
BACKGROUND: Peripheral neurotoxicity (PN) is a frequent side effect of oxaliplatin treatment, and also is its dose-limiting toxicity. Studies have confirmed that ω-3 polyunsaturated fatty acids (ω-3 PUFAs) had a neuroprotective effect. However, the efficacy of ω-3 PUFAs on the prevention of oxalipla...
Autores principales: | Zhang, Xinjie, Chen, Haitao, Lu, Yi, Xu, Chao, Yao, Wang, Xu, Lu, Zhang, Runzhe, Zhang, Liping, Yao, Qinghua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738088/ https://www.ncbi.nlm.nih.gov/pubmed/33327312 http://dx.doi.org/10.1097/MD.0000000000023564 |
Ejemplares similares
-
Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer
por: Aitini, Enrico, et al.
Publicado: (2012) -
The Use of Calcium and Magnesium to Prevent Neurotoxicity in Patients Receiving Oxaliplatin
por: Martyn, Karon, et al.
Publicado: (2015) -
Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial
por: Madi, A, et al.
Publicado: (2012) -
Identification of biomarkers predicting the chemotherapeutic outcomes of capecitabine and oxaliplatin in patients with gastric cancer
por: Zhang, Yan, et al.
Publicado: (2020) -
Network Pharmacology and Experimental Evidence Identify the Mechanism of Astragaloside IV in Oxaliplatin Neurotoxicity
por: Xu, Jingyu, et al.
Publicado: (2021)